SecBot SecBot

To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.

H.R. 7174 Rep. Gregory Murphy (R-NC-3) In committee
Bill text PDF
  1. Introduced Jan 31
  2. Committee Jan 31
  3. Passed House Next
  4. Passed Senate Not yet
  5. To President Not yet
  6. Law Not yet
Where it stands
In committee, Jan 31, 2024Next: House vote
680d ago Dec 17, 2024: Referred to the Subcommittee on Health.
Final votes
No roll callsNo recorded vote on this bill yet
Lobbying
9companies, 13 filings
Subscribe to see spend
Member trades
20trades in the last 90 days
Subscribe to see who
Who backs the bill and who pushes back Subscribe

Companies lobbying on this bill

9 companies
Companies by sector
Biotech & Pharma 9
Search all 9 companies, their asks and price moves Subscribe

Summary

This bill amends the Social Security Act to change the negotiation period for small-molecule drugs under the Medicare Drug Price Negotiation Program. It extends the time before a small-molecule drug becomes eligible for price negotiation from 7 years to 11 years, matching the period for biologic drugs.

Section 1, Equalizing the negotiation period: This section amends the Social Security Act by replacing the current 7-year period for small-molecule drugs with an 11-year period. The change applies retroactively as if it were part of the original law (Public Law 117-169).

Summary of the bill text as introduced in House (Jan 31, 2024), generated by SecBot from the official bill text; the Library of Congress summary is not yet published.

Official record from Congress.gov, the House Clerk and the Senate; lobbying from Lobbying Disclosure Act filings. Updated Oct 28, 2026.